- AU$30.65m
- AU$24.15m
- AU$4.05m
Brief: Emyria Posts FY Net Loss Attributable A$6.1 Million
Brief: Emyria Posts QTRLY Revenue Of A$1.53 MLN
Brief: Emyria Extends National Expansion Into New South Wales
Australia's Emyria rises to 5-month high after global services platform launch
Brief: Emyria Launches Global Services Platform Targeting International Drug Sponsors
Australia's Emyria rises on potential listing in Frankfurt exchange
Brief: Emyria Says Securities To Be Traded Via Frankfurt Quotation Board
Australia's Emyria slips on discounted placement
Brief: Emyria Says Institutional Placement Accelerates EMD National Expansion
Brief: Emyria Seeks Trading Halt
Australia's Emyria rises on depression treatment programme deal with Medibank
Brief: Emyria Says Medibank Signs Multi-Year Agreement To Fund Co's Depression Treatment
Brief: Emyria Announces Establishing Share Sale Facility For Holders Of "Less Than Marketable Parcels" Of Co's Shares
Australia's Emyria jumps on deal with Medibank, fund raising
Brief: Emyria Says Placement Of A$4M At A$0.024 Per Share
Brief: Emyria Seeks Trading Halt
Brief: Emyria Says Loss For Half-Year Attributable A$968,997
Australia's Emyria climbs to nearly two-month high on positive drug trial results
Brief: Emyria Says Greg Hutchinson Will Assume Role Of Executive Chair